Germany's Health Reform Law Stumbles Through Parliament
This article was originally published in The Pink Sheet Daily
Measure will curtail manufacturer latitude on drug pricing, especially for new drugs not shown to have added benefit over existing products.
You may also be interested in...
Novartis has withdrawn its oral anti-diabetic Galvus from the German market after failing to secure a mutually beneficial price with payers. Galvus is the only drug dropped from reimbursement under a since-repealed policy to assess added benefits of brand drugs marketed before 2011.
GSK believes detrimental government policies such as reference pricing and tendering in the vaccines sector are threatening this part of the pharmaceutical industry, and patient health.
Germany’s senior reimbursement body, the G-BA, has announced it will assess a second wave of older drugs, despite a pending coalition agreement dropping this practice.